Engineering allogeneic CAR-T to build translational capabilities for solid tumors amenable to locoregional delivery
At T-MAXIMUM we are at the forefront of a medical revolution, harnessing the transformative potential of engineered T cells to address diseases once considered untreatable.
Our mission is to reshape the landscape of modern medicine by developing innovative therapies that bring hope and healing to patients worldwide.
Focus on locoregionally accessible solid tumors
With recurrent glioblastoma as our first validation setting, we are expanding into intracranial tumors such as brain metastases. We look beyond imaging changes to broader clinical benefit, including survival, neurological function, symptom control and quality of life.
Product design and manufacturing
Starting with healthy donor cells, we are building a product system spanning engineering, scalable manufacturing, cryopreservation and quality control. It supports reliable supply for multicenter clinical development and exploration of repeat-dosing strategies.
Allogeneic compatibility and clinical development
We are progressively building clinical experience around allogeneic compatibility, locoregional delivery, safety monitoring, dose and schedule, and long-term follow-up to inform product iteration and indication expansion.
The strides we've made in the complex field of cell drug development are largely attributable to our executive team's deep well of experience and expertise. This team, comprising industry veterans with a proven track record in cell therapy development, brings together a wealth of knowledge in biotechnology, pharmaceuticals, and clinical research.
